Does KIDS pay a dividend and is it safe?

OrthoPediatrics Corp. (KIDS) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / KIDS / dividends

BBNX (36) SIBN (52) IRMD (55) IART (19) ⌘ Pro Terminal →

OrthoPediatrics Corp. (KIDS) Dividend Safety Gauge & 10-Year DRIP Compounder

$30.43 -1.42% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $30.29

OrthoPediatrics Corp. (KIDS) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $806.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KIDS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KIDS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, OrthoPediatrics Corp. (NASDAQ: KIDS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $30.43 (-1.42% 1D, market cap $806.0M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, KIDS ranks #263 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KIDS compare to BBNX and SIBN in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), KIDS carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 73.1%, and ROIC of -7.3%. By comparison, BBNX (Beta Bionics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -22.1%, cap $910.6M) and SIBN (SI-BONE Inc.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC -10.3%, cap $951.5M). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KIDS?

▼

Per KIDS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001425450), OrthoPediatrics Corp. generated $236.3M in revenue (+15.4% YoY), -$39.6M in net income, and -$16.0M in free cash flow against $508.6M in total assets and $99.8M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $30.29 (-0.45%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-3.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KIDS)Realized 20D OHLCV Swing Band: ±10.3%

Deterministic 5-Pillar Attribution (50/100 Composite)

🔍 WHY KIDS SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (32% of score)

20D Institutional Volume Accumulation (±10.3% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (24% of score)

Altman Z-Score 3.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$21.93+7.2% Next Q

Q2 (-2Q)

Grade D$23.50+1.4% Next Q

Q3 (-1Q)

Grade D$23.82+27.7% Next Q

Current

Grade D$30.43-1.4% Hist 90D α

Trajectory: D (42) → D (50)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KIDS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KIDS currently carries a cautious 50/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.56) and Max Pain ($31.95) forces dealer call-delta covering toward $34.61.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KIDS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “KIDS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 50%NO 50%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (9.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $23,892

Est. Year-10 Shareholder Yield: $143/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.9K

Yr 1

$11.9K

Yr 2

$13.0K

Yr 3

$14.2K

Yr 4

$15.5K

Yr 5

$16.9K

Yr 6

$18.4K

Yr 7

$20.1K

Yr 8

$21.9K

Yr 9

$23.9K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KIDS)

✓Walkthrough of KIDS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KIDS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +92.84%▲ ASCENDING CHANNEL

2026-11-03O $31.52H $31.52L $30.43C $30.43VOL 570.0K

RES: $32.98SUP: $22.25SMA50: $23.56SMA200: $19.69

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KIDS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KIDS Butterfly Map → + Track KIDS →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +15.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on KIDS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KIDS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KIDS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KIDS)

Health Care Rank #263 of 1015 ⚔️ BBNX vs KIDS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KIDS vs. BBNX, SIBN, IRMD, IART)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, OrthoPediatrics Corp. (KIDS) ranks #263 by composite RQD confidence (50/100, grade D) and #381 by equity capitalization ($806.0M). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with KIDS at 50/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KIDS ACTIVE OrthoPediatrics Corp.	D	50/100	—	73.1%	-7.3%	-1.42%	$806.0M	Benchmark Subject
BBNX Beta Bionics Inc.	D-	36/100	—	55.4%	-22.1%	-5.07%	$910.6M	/bbnx-vs-kids →
SIBN SI-BONE Inc.	D+	52/100	—	79.6%	-10.3%	-4.76%	$951.5M	/sibn-vs-kids →
IRMD iRadimed Corporation	D+	55/100	48.8x	76.7%	37.7%	+3.57%	$980.5M	/irmd-vs-kids →
IART Integra LifeSciences Holdings Corporation	E	19/100	—	50.9%	-35.0%	+6.75%	$992.0M	/iart-vs-kids →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001425450 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), OrthoPediatrics Corp. (KIDS) reported GAAP revenue of $236.3M (+15.4% vs. FY2024 revenue of $204.7M , and +58.9% cumulative change since FY2023) , GAAP net income of -$39.6M, operating cash flow of -$4.9M, and free cash flow of -$16.0M (+61.4% YoY). On the balance sheet, KIDS closed FY2025 with $508.6M in total assets against $99.8M in total debt (Altman Z-Score: 3.00, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$236.3M	-$39.6M	-$4.9M	-$16.0M	$508.6M	$99.8M
FY2024 (FY)	2024-12-31	$204.7M	-$37.8M	-$27.0M	-$41.3M	$473.2M	$73.0M
FY2023 (FY)	2023-12-31	$148.7M	-$21.0M	-$27.0M	-$27.0M	—	—

3. KIDS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KIDS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does KIDS compare to BBNX and SIBN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for KIDS?

Where is KIDS trading relative to its 50-day, 200-day, and 52-week technical levels?

KIDS last traded at $30.43 (-1.42% on volume of 488,156 shares), positioning the stock +29.16% above its 50-day simple moving average ($23.56) and +54.55% above its 200-day simple moving average ($19.69). Across its 52-week range of $14.42 to $32.62, KIDS sits at the 88.0% percentile with a 14-day RSI of 74.7 (OVERBOUGHT (>70)) and an implied next-earnings move of ±10.3% ($27.30 to $33.56).

Direct Sub-Reports: KIDS RQD Cockpit KIDS 12M Forecast KIDS Earnings & Move KIDS Dividends & DRIP KIDS Insiders & 13F KIDS Whale Options KIDS Profit Sankey KIDS News & Why

ROARABLE RATING BRIEF • RQD 50/100 (D) ✓ SEC XBRL & RQD VERIFIED

KIDS — OrthoPediatrics Corp.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

OrthoPediatrics Corp. (KIDS) earns a live Roarable RQD composite score of 50/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $30.43 (-1.42% 1D, market capitalization $806.0M).

Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -7.3%, gross margin of 73.1%, operating margin of -16.6%, and free cash flow yield of -1.94%.
Whale 13F & Options Flow (16/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (12/20): Incorporates a 1.00x equity beta, Altman Z-Score of 3.00, Piotroski F-Score of 5/9, and Debt/Equity of 0.29x.

2. Business Model, Unit Margins & SEC Financial Trajectory

OrthoPediatrics Corp. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. The company's market capitalization is $0.8B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), OrthoPediatrics Corp. (KIDS) reported $236.3M in annual revenue (up from $204.7M in FY2024, +15.4% YoY) and -$39.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($148.7M revenue, -$21.0M net income) through FY2025, KIDS scaled operating cash flow to -$4.9M and free cash flow to -$16.0M, backed by $508.6M in total assets against $99.8M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D • RQD 50/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -1.94% and institutional whale pillar of 16/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $14.42 – $32.62 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -16.6% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — The sector is recorded as Health Care and the industry as Medical/Dental Instruments, but the source does not map any specific suppliers, customers, or peers.

Key Question #1: Can KIDS sustain or expand its -16.6% operating margin and -7.3% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $236.3M and free cash flow of -$16.0M, how will capital allocation balance growth reinvestment against $99.8M in total debt?
Key Question #3: How sensitive is KIDS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

KIDS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for OrthoPediatrics Corp. (KIDS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KIDS Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

OrthoPediatrics Corp. (KIDS) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering OrthoPediatrics Corp. (KIDS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

OrthoPediatrics (KIDS) Stock Sees Fair Value Lift After Higher Growth And New Product Wins

Yahoo Finance report covering OrthoPediatrics Corp. (KIDS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Stock Titan • 1d ago

Nearly 42,000 children were helped in one quarter. OrthoPediatrics raised its 2026 revenue forecast.

Stock Titan report covering OrthoPediatrics Corp. (KIDS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

US$30.75 - That's What Analysts Think OrthoPediatrics Corp. (NASDAQ:KIDS) Is Worth After These Results

Simply Wall St report covering OrthoPediatrics Corp. (KIDS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StocksToTrade • 1d ago

OrthoPediatrics Climbs 6% After Raising Guidance

StocksToTrade report covering OrthoPediatrics Corp. (KIDS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 1d ago

OrthoPediatrics (KIDS) Reports Q3 Loss, Tops Revenue Estimates

Yahoo Finance report covering OrthoPediatrics Corp. (KIDS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

How Orthopediatrics Corp. (KIDS) Affects Rotational Strategy Timing

Stock Traders Daily report covering OrthoPediatrics Corp. (KIDS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stock Titan • 1d ago

Revenue rose 19% at OrthoPediatrics (KIDS), while its quarterly net loss narrowed.

Stock Titan report covering OrthoPediatrics Corp. (KIDS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KIDS Bull vs. Bear Conversation Board — What's Your Call at $30.43?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KIDS 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $40.13 (+30.0%)

📌 Pinned Debate

Institutional accumulation (Whale 13F pillar at 16/20) and recent guidance raises support upside momentum.

Here is why I am bullish on KIDS here at $30.87: Institutional accumulation (Whale 13F pillar at 16/20) and recent guidance raises support upside momentum.. Compare KIDS's -16.6% operating margin and -7.3% ROIC against the rest of Medical/Dental Instruments. As long as cash conversion holds up, dips toward $29.33 are getting bought.

SectorRotator 🐂 BULL

@MultipleCompression Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (73.1%) holds, EPS grows into the multiple faster than bears think.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $25.31 (-18.0%)

Spot @ $30.87

Negative ROIC of -7.3%, negative FCF yield of -1.94%, and weak insider conviction (3/20) signal the stock is priced above its cash-gene

Sitting on the sidelines or leaning short KIDS above $30.87. Negative ROIC of -7.3%, negative FCF yield of -1.94%, and weak insider conviction (3/20) signal the stock is priced above its cash-generation fundamentals.. Until Fundamental Cash Engine (9/20) and FCF yield (-1.94%) inflect higher, upside is capped near $32.62.